What is the 13F Pro Quality Score for RANI?

13F Pro ranks Rani Therapeutics Holdings, Inc. (RANI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RANI's current score at https://13fpro.ai/company/RANI (free sign-up required for the full ranking).

Where does 13F Pro source RANI data?

All Rani Therapeutics Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Rani Therapeutics Holdings, Inc. files with the SEC under CIK 1856725. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RANI in?

Rani Therapeutics Holdings, Inc. (RANI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RANI research updated on 13F Pro?

RANI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Rani Therapeutics Holdings, Inc.(RANI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1856725 RANI stock profile & AI dashboard →

13F Pro Quality Score

28.5/100

Rank #2,555 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why RANI Scores 29/100

exact factor attribution · 2026-09-11

RANI's composite is driven by revenue growth, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.2 pts

96th pct

Earnings growth

-1.1 pts

27th pct

Earnings quality

-1.2 pts

38th pct

Institutional flow

-1.9 pts

12th pct

Shareholder dilution

-2.4 pts

2th pct

Capital efficiency

-4.5 pts

6th pct

Profitability

-6.5 pts

7th pct

Free cash flow

-6.5 pts

7th pct

Scale

-6.7 pts

5th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

RANI Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Rani Therapeutics Holdings, Inc. (RANI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RANI at 28.5/100 on a 32-signal composite quality model, placing it at rank #2,555 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Rani Therapeutics Holdings, Inc. reports quarterly revenue of $1.7M, net income of $-7.4M, free cash flow of $-9.1M. Top institutional holders of RANI by reported 13-F value include Samsara BioCapital, RA CAPITAL MANAGEMENT, L.P., AWM Investment Company, based on the most recent SEC filings. RANI trades on the Nasdaq exchange and files with the SEC under CIK 1856725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RANI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Rani Therapeutics Holdings, Inc. directly from SEC EDGAR. Rani Therapeutics Holdings, Inc.'s 13F Pro composite quality score has ranged between 10 and 29 since 2026, currently 28.5 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about Rani Therapeutics Holdings, Inc.

Quirks, history, and lore behind RANI — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in San Jose, California · focused on transforming injectable drugs into oral therapies.
2
The Numbers
A small-cap company with minimal revenue, as expected for a firm still in clinical trials — burning cash while betting its pipeline will reshape how patients take their medicine.
3
The History
Founded in the 2010s, it spun out of InCube Labs, a prolific medical device and biotech incubator, and went public via a traditional IPO in the early 2020s.
4
The Secret
Its core trick is a tiny robotic pill — an ingestible capsule that self-orients in the stomach and injects drug directly into the GI wall, bypassing the needle entirely.
5
The Lore
Its lead programs target large-molecule biologics — drugs like those used in rheumatoid arthritis and inflammatory bowel disease — categories where patients currently have no oral option.
6
The Giveaway
Named after a Hindu princess, this company's signature platform is literally called the Rani Pill — a self-injecting capsule designed to make your biologic shot a thing of the past.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$1.7M

Net Income

Q2 2026

$-7.4M

Free Cash Flow

Q2 2026

$-9.1M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+58.9% YoY

$1.6MFY 2025

FY22 $0.00FY23 $0.00FY24 $1.0MFY25 $1.6M

Net Income

+1.1% YoY

$-29.7MFY 2025

FY22 $-30.6MFY23 $-34.0MFY24 $-30.0MFY25 $-29.7M

Operating Income

+28.1% YoY

$-38.3MFY 2025

FY22 $-63.5MFY23 $-66.1MFY24 $-53.3MFY25 $-38.3M

EPS (Diluted)

+57.1% YoY

$-0.45FY 2025

FY22 $-1.28FY23 $-1.33FY24 $-1.05FY25 $-0.45

Total Assets

+60.0% YoY

$58.6MFY 2025

FY22 $108.0MFY23 $57.9MFY24 $36.6MFY25 $58.6M

Total Debt

-100.0% YoY

$0.00FY 2025

FY22 $30.0MFY23 $34.9MFY24 $40.0MFY25 $0.00

Op. Cash Flow

+47.3% YoY

$-18.7MFY 2025

FY22 $-46.5MFY23 $-51.2MFY24 $-35.5MFY25 $-18.7M

Free Cash Flow

+47.4% YoY

$-18.8MFY 2025

FY22 $-48.1MFY23 $-52.5MFY24 $-35.8MFY25 $-18.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.6M +58.9%	$1.0M	$0.00	$0.00 -100.0%	$2.7M +488.1%	$462.0K
Net Income	$-29.7M +1.1%	$-30.0M +11.6%	$-34.0M -11.1%	$-30.6M -267.2%	$-8.3M	—
Operating Income	$-38.3M +28.1%	$-53.3M +19.3%	$-66.1M -4.2%	$-63.5M -23.0%	$-51.6M -211.9%	$-16.5M
EPS (Diluted)	$-0.45 +57.1%	$-1.05 +21.1%	$-1.33 -3.9%	$-1.28 -197.7%	$-0.43	—
Total Assets	$58.6M +60.0%	$36.6M -36.7%	$57.9M -46.4%	$108.0M -13.0%	$124.2M +56.4%	$79.4M
Total Debt	$0.00 -100.0%	$40.0M +14.6%	$34.9M +16.3%	$30.0M	$0.00 -100.0%	$3.8M
Operating Cash Flow	$-18.7M +47.3%	$-35.5M +30.7%	$-51.2M -10.1%	$-46.5M -44.3%	$-32.2M -115.5%	$-15.0M
Free Cash Flow	$-18.8M +47.4%	$-35.8M +31.8%	$-52.5M -9.0%	$-48.1M -47.0%	$-32.8M -102.7%	$-16.2M

Get alerted when RANI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Rani Therapeutics Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RANI

Samsara BioCapital, LLC
$7.9M10,369,159 sh
RA CAPITAL MANAGEMENT, L.P.
$6.5M8,500,000 sh
AWM Investment Company, Inc.
$5.7M7,500,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.5M4,562,985 sh
Longaeva Partners L.P.
$1.8M2,329,459 sh
Polar Asset Management Partners Inc.
$1.8M2,318,542 sh
Siren, L.L.C.
$1.5M2,000,000 sh
HEIGHTS CAPITAL MANAGEMENT, INC
$710.7K934,580 sh
GEODE CAPITAL MANAGEMENT, LLC
$677.6K890,618 sh
CITADEL ADVISORS LLC
$488.2K641,995 sh

Fund	Value	Shares
Samsara BioCapital, LLC	$7.9M	10,369,159
RA CAPITAL MANAGEMENT, L.P.	$6.5M	8,500,000
AWM Investment Company, Inc.	$5.7M	7,500,000
VANGUARD CAPITAL MANAGEMENT LLC	$3.5M	4,562,985
Longaeva Partners L.P.	$1.8M	2,329,459
Polar Asset Management Partners Inc.	$1.8M	2,318,542
Siren, L.L.C.	$1.5M	2,000,000
HEIGHTS CAPITAL MANAGEMENT, INC	$710.7K	934,580
GEODE CAPITAL MANAGEMENT, LLC	$677.6K	890,618
CITADEL ADVISORS LLC	$488.2K	641,995

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RANI on your watchlist

Track score changes the day Rani Therapeutics Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RANI a good stock to buy?

13F Pro's AI-powered analysis of Rani Therapeutics Holdings, Inc. (RANI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RANI are available on the RANI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RANI is classified as a small company.

Which hedge funds own RANI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RANI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Rani Therapeutics Holdings, Inc.'s investment landscape.